Cargando…

Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics

To better understand the transcriptomic interplay of organisms associated with lymphatic filariasis, we conducted multispecies transcriptome sequencing (RNA-Seq) on the filarial nematode Brugia malayi, its Wolbachia endosymbiont wBm, and its laboratory vector Aedes aegypti across the entire B. malay...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Matthew, Teigen, Laura E., Libro, Silvia, Bromley, Robin E., Olley, Dustin, Kumar, Nikhil, Sadzewicz, Lisa, Tallon, Luke J., Mahurkar, Anup, Foster, Jeremy M., Michalski, Michelle L., Dunning Hotopp, Julie C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890932/
https://www.ncbi.nlm.nih.gov/pubmed/31796568
http://dx.doi.org/10.1128/mSystems.00596-19
_version_ 1783475718242435072
author Chung, Matthew
Teigen, Laura E.
Libro, Silvia
Bromley, Robin E.
Olley, Dustin
Kumar, Nikhil
Sadzewicz, Lisa
Tallon, Luke J.
Mahurkar, Anup
Foster, Jeremy M.
Michalski, Michelle L.
Dunning Hotopp, Julie C.
author_facet Chung, Matthew
Teigen, Laura E.
Libro, Silvia
Bromley, Robin E.
Olley, Dustin
Kumar, Nikhil
Sadzewicz, Lisa
Tallon, Luke J.
Mahurkar, Anup
Foster, Jeremy M.
Michalski, Michelle L.
Dunning Hotopp, Julie C.
author_sort Chung, Matthew
collection PubMed
description To better understand the transcriptomic interplay of organisms associated with lymphatic filariasis, we conducted multispecies transcriptome sequencing (RNA-Seq) on the filarial nematode Brugia malayi, its Wolbachia endosymbiont wBm, and its laboratory vector Aedes aegypti across the entire B. malayi life cycle. In wBm, transcription of the noncoding 6S RNA suggests that it may be a regulator of bacterial cell growth, as its transcript levels correlate with bacterial replication rates. For A. aegypti, the transcriptional response reflects the stress that B. malayi infection exerts on the mosquito with indicators of increased energy demand. In B. malayi, expression modules associated with adult female samples consistently contained an overrepresentation of genes involved in chromatin remodeling, such as the bromodomain-containing proteins. All bromodomain-containing proteins encoded by B. malayi were observed to be upregulated in the adult female, embryo, and microfilaria life stages, including 2 members of the bromodomain and extraterminal (BET) protein family. The BET inhibitor JQ1(+), originally developed as a cancer therapeutic, caused lethality of adult worms in vitro, suggesting that it may be a potential therapeutic that can be repurposed for treating lymphatic filariasis. IMPORTANCE The current treatment regimen for lymphatic filariasis is mostly microfilaricidal. In an effort to identify new drug candidates for lymphatic filariasis, we conducted a three-way transcriptomics/systems biology study of one of the causative agents of lymphatic filariasis, Brugia malayi, its Wolbachia endosymbiont wBm, and its vector host Aedes aegypti at 16 distinct B. malayi life stages. B. malayi upregulates the expression of bromodomain-containing proteins in the adult female, embryo, and microfilaria stages. In vitro, we find that the existing cancer therapeutic JQ1(+), which is a bromodomain and extraterminal protein inhibitor, has adulticidal activity in B. malayi.
format Online
Article
Text
id pubmed-6890932
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-68909322019-12-16 Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics Chung, Matthew Teigen, Laura E. Libro, Silvia Bromley, Robin E. Olley, Dustin Kumar, Nikhil Sadzewicz, Lisa Tallon, Luke J. Mahurkar, Anup Foster, Jeremy M. Michalski, Michelle L. Dunning Hotopp, Julie C. mSystems Research Article To better understand the transcriptomic interplay of organisms associated with lymphatic filariasis, we conducted multispecies transcriptome sequencing (RNA-Seq) on the filarial nematode Brugia malayi, its Wolbachia endosymbiont wBm, and its laboratory vector Aedes aegypti across the entire B. malayi life cycle. In wBm, transcription of the noncoding 6S RNA suggests that it may be a regulator of bacterial cell growth, as its transcript levels correlate with bacterial replication rates. For A. aegypti, the transcriptional response reflects the stress that B. malayi infection exerts on the mosquito with indicators of increased energy demand. In B. malayi, expression modules associated with adult female samples consistently contained an overrepresentation of genes involved in chromatin remodeling, such as the bromodomain-containing proteins. All bromodomain-containing proteins encoded by B. malayi were observed to be upregulated in the adult female, embryo, and microfilaria life stages, including 2 members of the bromodomain and extraterminal (BET) protein family. The BET inhibitor JQ1(+), originally developed as a cancer therapeutic, caused lethality of adult worms in vitro, suggesting that it may be a potential therapeutic that can be repurposed for treating lymphatic filariasis. IMPORTANCE The current treatment regimen for lymphatic filariasis is mostly microfilaricidal. In an effort to identify new drug candidates for lymphatic filariasis, we conducted a three-way transcriptomics/systems biology study of one of the causative agents of lymphatic filariasis, Brugia malayi, its Wolbachia endosymbiont wBm, and its vector host Aedes aegypti at 16 distinct B. malayi life stages. B. malayi upregulates the expression of bromodomain-containing proteins in the adult female, embryo, and microfilaria stages. In vitro, we find that the existing cancer therapeutic JQ1(+), which is a bromodomain and extraterminal protein inhibitor, has adulticidal activity in B. malayi. American Society for Microbiology 2019-12-03 /pmc/articles/PMC6890932/ /pubmed/31796568 http://dx.doi.org/10.1128/mSystems.00596-19 Text en Copyright © 2019 Chung et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Chung, Matthew
Teigen, Laura E.
Libro, Silvia
Bromley, Robin E.
Olley, Dustin
Kumar, Nikhil
Sadzewicz, Lisa
Tallon, Luke J.
Mahurkar, Anup
Foster, Jeremy M.
Michalski, Michelle L.
Dunning Hotopp, Julie C.
Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_full Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_fullStr Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_full_unstemmed Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_short Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_sort drug repurposing of bromodomain inhibitors as potential novel therapeutic leads for lymphatic filariasis guided by multispecies transcriptomics
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890932/
https://www.ncbi.nlm.nih.gov/pubmed/31796568
http://dx.doi.org/10.1128/mSystems.00596-19
work_keys_str_mv AT chungmatthew drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT teigenlaurae drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT librosilvia drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT bromleyrobine drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT olleydustin drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT kumarnikhil drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT sadzewiczlisa drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT tallonlukej drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT mahurkaranup drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT fosterjeremym drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT michalskimichellel drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT dunninghotoppjuliec drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics